Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 20/20 | 0.94 |
| ▸ | HTR1A | P08908 | 19/20 | 0.94 |
| ▸ | HTR1B | P28222 | 19/20 | 0.94 |
| ▸ | SLC6A4 | P31645 | 16/20 | 0.94 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.94 |
| ▸ | DRD2 | P14416 | 1/20 | 0.94 |
| ▸ | HTR2A | P28223 | 1/20 | 0.94 |
| ▸ | HTR2C | P28335 | 1/20 | 0.94 |
| ▸ | HTR2B | P41595 | 1/20 | 0.94 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4176638 | 0.99 | HTR1D (0.92) | HTR1DHTR1AHTR1BSLC6A4KCNH2 | |
| SCHEMBL4167325 | 0.97 | HTR1D (1.00) | HTR1DHTR1AHTR1BSLC6A4KCNH2 | |
| Hydrochloric Acid SCHEMBL4173781 | 0.96 | HTR1D (0.98) | HTR1DHTR1AHTR1BSLC6A4KCNH2 | |
| SCHEMBL4182246 | 0.91 | HTR1A (1.00) | HTR1DHTR1AHTR1BSLC6A4KCNH2 | |
| Hydrochloric Acid SCHEMBL4186568 | 0.90 | HTR1A (0.98) | HTR1DHTR1AHTR1BSLC6A4KCNH2 | |
| SCHEMBL2301809 | 0.89 | HTR1A (0.94) | HTR1DHTR1AHTR1BSLC6A4KCNH2 | |
| SCHEMBL4177932 | 0.88 | HTR1D (1.00) | HTR1DHTR1AHTR1BSLC6A4KCNH2 | |
| Hydrochloric Acid SCHEMBL4189370 | 0.88 | HTR1A (0.92) | HTR1DHTR1AHTR1BSLC6A4KCNH2 | |
| SCHEMBL4172012 | 0.87 | HTR1A (1.00) | HTR1DHTR1AHTR1BSLC6A4KCNH2 | |
| Hydrochloric Acid SCHEMBL4186394 | 0.86 | HTR1A (0.98) | HTR1DHTR1AHTR1BSLC6A4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4741842-B2 | — | — | 2011-08-10 | — | — | JP | claimed |
| US-20060264429-A1 | Benzoxazinone derivatives, preparation thereof and uses in the treatment of cns and other disorders | GLAXO GROUP LIMITED (GB) | 2006-11-23 | — | — | US | claimed |
| EP-1562917-A1 | BENZOXAZINONE DERIVATIVES, PREPARATION THEREOF AND USES IN THE TREATMENT OF CNS AND OTHER DISORDERS | GLAXO GROUP LIMITED (GB) | 2005-08-17 | — | — | EP | claimed |
| WO-2004046124-A1 | BENZOXAZINONE DERIVATIVES, PREPARATION THEREOF AND USES IN THE TREATMENT OF CNS AND OTHER DISORDERS | GLAXO GROUP LIMITED (GB) | 2004-06-03 | — | — | WO | claimed |
| US-20090076274-A1 | BENZOXAZINONE DERIVATIVES, PREPARATION THEREOF AND USES IN THE TREATMENT OF CNS AND OTHER DISORDERS | GLAXO GROUP LIMITED | 2009-03-19 | — | — | US | disclosed |
| US-20060264429-A1 | Benzoxazinone derivatives, preparation thereof and uses in the treatment of cns and other disorders | GLAXO GROUP LIMITED (GB) | 2006-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264429-A1 | Benzoxazinone derivatives, preparation thereof and uses in the treatment of cns and other disorders | XDH, CYP4X1, PDHX | HTR1D 75/4885HTR1A 47/4885HTR1B 39/4885 |
| US-20090076274-A1 | BENZOXAZINONE DERIVATIVES, PREPARATION THEREOF AND USES IN THE TREATMENT OF CNS AND OTHER DISORDERS | XDH, CYP4X1, PDHX | HTR1D 569/4885HTR1A 476/4885HTR1B 252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.